| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Imisopasem manganese (M40403, GC4419) is a novel, potent, manganese-based and non-peptidyl mimetic of the human mitochondrial manganese superoxide dismutase (MnSOD), with potential antioxidant and chemo/radioprotective activities. Imisopasem manganese mimics the activity of MnSOD and scavenges reactive oxygen species (ROS), such as superoxide anion, which prevents oxygen free radical damage to macromolecules such as DNA. This reduces ROS-mediated lipid peroxidation, prevents apoptosis and protects against oxygen free radical-induced toxicity in normal tissues.
| ln Vitro |
Manganese imisoparsonin is a synthetic manganese small molecule that contains a superoxide dismutase mimetic (SODm) that eliminates superoxide anions without interfering with other active ingredients including nitric oxide (NO) and peroxynitrite (ONOO-) that are known to be involved in inflammatory responses [1].
|
|---|---|
| ln Vivo |
A small chemical superoxide dismutase mimic called imisomersonin has demonstrated effectiveness in animal model illness situations where superoxide anion is believed to be important. The inflammatory response in rats following intrapleural injection of carrageenan is inhibited by manganese imisoparsonin. All inflammatory indicators were reduced by imisopasem manganese, with the exception of NOx, PGE2, and IL-10, which did not decrease [1]. Imisopasem manganese pretreatment led to a considerable restoration of lymphoid and hematopoietic tissue in the large intestine (particularly the small intestine) and decreased cell death. Imisoparsonite has the potential to be a novel radioprotective agent that can effectively lessen tissue damage brought on by traumatic brain injury [2].
|
| References |
|
| Additional Infomation |
M40403 is a low molecular weight, synthetic manganese containing superoxide dismutase mimetic (SODm) that selectively removes superoxide anion.
Imisopasem Manganese is a manganese-based non-peptidyl mimetic of the human mitochondrial manganese superoxide dismutase (MnSOD), with potential antioxidant and chemo/radioprotective activities. Upon administration, imisopasem manganese mimics the activity of MnSOD and scavenges reactive oxygen species (ROS), such as superoxide anion, which prevents oxygen free radical damage to macromolecules such as DNA. This reduces ROS-mediated lipid peroxidation, prevents apoptosis and protects against oxygen free radical-induced toxicity in normal tissues. Drug Indication Intended for the treatment of pain and possibly various forms of cancer. Mechanism of Action M40403 is the lead candidate in a unique class of compounds known as superoxide dismutase (SOD) mimetics. These stable, low molecular weight compounds mimic the effect of superoxide dismutase, a naturally occurring enzyme designed to destroy superoxide free radicals present in various diseases associated with pain and inflammation. Pharmacodynamics M40403 treatment exerts a protective effect against ischaemia-reperfusion-induced myocardial injury, supporting a key role for superoxide anion in reperfusion injuries. |
| Molecular Formula |
C21H35CL2MNN5
|
|---|---|
| Molecular Weight |
483.3802
|
| Exact Mass |
482.164
|
| CAS # |
218791-21-0
|
| PubChem CID |
10195666
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.77
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
29
|
| Complexity |
381
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1CC[C@@H]2[C@@H](C1)NCCN[C@@H]3CCCC[C@H]3NCC4=CC=CC(=N4)CN2.[Cl-].[Cl-].[Mn+2]
|
| InChi Key |
WXEMWBBXVXHEPU-XNPJUPKFSA-L
|
| InChi Code |
InChI=1S/C21H35N5.2ClH.Mn/c1-3-10-20-18(8-1)22-12-13-23-19-9-2-4-11-21(19)25-15-17-7-5-6-16(26-17)14-24-20;;;/h5-7,18-25H,1-4,8-15H2;2*1H;/q;;;+2/p-2/t18-,19-,20-,21-;;;/m1.../s1
|
| Chemical Name |
Manganese,
dichloro[(4aR,13aR,17aR,21aR)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7Hdibenzo[b,h][1,4,7,10]tetraazacycloheptadecine-κN5,κN13,κN18,κN21,κN22]-,
(PB-7-11-2344'3')-.
|
| Synonyms |
M40403 M 40403 M-40403 CG4419 CG 4419 CG-4419 SC72325 SC-72325 SC 72325
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~25 mg/mL (~52.15 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 8.33 mg/mL (17.38 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0688 mL | 10.3438 mL | 20.6877 mL | |
| 5 mM | 0.4138 mL | 2.0688 mL | 4.1375 mL | |
| 10 mM | 0.2069 mL | 1.0344 mL | 2.0688 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00101621 | TERMINATED | Drug: M40403 | Cancer Pain |
MetaPhore Pharmaceuticals | 2004-08 | Phase 2 |
| NCT00033956 | SUSPENDED | Drug: M40403 | IL-2 Induced Hypotension | MetaPhore Pharmaceuticals | 2001-12 | Phase 1 Phase 2 |
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
